05:10 PM EDT, 03/26/2026 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said late Thursday it has filed a marketing authorization application with Brazil's National Health Surveillance Agency for its oral acromegaly treatment, Palsonify, for use in adults.

Acromegaly is a hormonal condition that causes excess growth of certain body parts.

The filing is supported by 18 clinical trials, including two phase 3 studies, which showed significant improvements in biochemical markers and symptom management versus placebo, along with good tolerability, the company said.

Palsonify is approved in the US for adults who did not respond to surgery or are ineligible for surgery, and it recently received a favorable opinion from the European Union's Committee for Medicinal Products for Human Use, the company added.